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Rationale—Ziprasidone is an atypical antipsychotic recommended to be administered twice
daily.
Objectives—The purpose of this study was to investigate whether occupancy of the dopamine
D2/3 receptors by ziprasidone is maintained across a day employing a within subject design.
Methods—Positron Emission Tomography (PET) scans with [11C]-raclopride were performed in
12 patients with schizophrenia while treated with ziprasidone 60mg twice daily. Each patient
completed [11C]-raclopride PET scans at 5, 13 and 23 hours after the last dose of ziprasidone.
Dopamine D2/3 receptor occupancy was estimated with reference to binding potential data of 44
age- and sex-matched control subjects in the caudate, putamen and ventral striatum.
Results—Eleven scans were available at each time point, and the mean occupancies at 5-, 13-
and 23-hour scans were 66%, 39% and 2% in the putamen; 62%, 35% and −6% in the caudate;
and 68%, 47% and 11% in the ventral striatum, respectively. The time-course of receptor
occupancy across the regions indicated an occupancy half-life of 8.3 hours. The serum level of
ziprasidone associated with 50% D2/3 receptors occupancy was estimated to be 204nmol/L (84ng/
ml). Prolactin levels were highest at 5-hour post-dose and none showed hyperprolactinemia at 23-
hour scans.
Conclusions—The absence of ziprasidone striatal D2/3 receptor binding 23-hour after taking 60
mg under steady state conditions is consistent with its peripheral half-life. The results support our
earlier report that ziprasidone 60 mg administered twice daily appears to be the minimal dose
expected to achieve therapeutic central dopamine D2 receptor occupancy (i.e. 60%).
Keywords
[11C]-raclopride; dopamine D2 receptor; pharmacokinetics; Positron Emission Tomography;
schizophrenia; ziprasidone
Introduction
Ziprasidone is an atypical antipsychotic shown to be effective in the treatment of
schizophrenia and schizoaffective disorder (Daniel et al. 1999; Hirsch et al. 2002; Simpson
et al. 2005; Stahl et al. 2010). Ziprasidone given 80–160 mg per day in divided dosage has
been shown to be effective in treating positive, negative and affective symptoms with
relatively low incidence of extrapyramidal side effects (EPS), weight gain, and metabolic
side effects (Citrome 2009). Since ziprasidone has a relatively short peripheral half-life (6–7
hours), it is currently recommended to be taken in divided dosage – typically twice a day,
with food (Caley and Cooper 2002).
Positron emission tomography (PET) studies have demonstrated a therapeutic window of
striatal dopamine D2/3 receptor blockade by antipsychotics in vivo. Clinical response has
been associated with 60–70% D2/3 receptor blockade and 80% or more has been associated
with EPS (Farde et al. 1988; Kapur et al. 1995; Kapur et al. 2000a; Pilowsky et al. 1993).
We have previously shown, using the radiotracer [11C]-raclopride, that ziprasidone (40–
160mg/day) continued to occupy 56±18% of D2/3 receptors at expected plasma trough levels
(12–16 hours post-dose) (Mamo et al. 2004). Recently, Vernaleken et al. (Vernaleken et al.
2008) have shown using the radiotracer [18F]-fallypride, that ziprasidone (80–160mg/day)
continued to occupy 59% of D2/3 receptors in the putamen 7.4 hours post-dose. These results
taken together, ziprasidone may continue to significantly occupy D2/3 receptors in the
striatum at plasma trough levels.
However, the previous studies have employed a between-subjects design, and have not
demonstrated continued D2/3 receptor occupancy beyond the predicted pharmacokinetics of
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ziprasidone within the same subjects with schizophrenia over time. A within-subjects design
would more robustly determine whether there is a discrepancy between the time course of
ziprasidone’s plasma concentration and D2/3 receptor occupancy in the striatum.
Using multiple [11C]-raclopride PET scans within the same subjects, we sought to
characterize ziprasidone’s (60mg, twice a day) occupancy at the D2/3 receptors in relation to
its peripheral pharmacokinetics over the 24 hours in patients with schizophrenia. Elucidating
the relationship between ziprasidone’s central occupancy and peripheral pharmacokinetics
will help inform optimal dosage frequency in the future; an important predictor of treatment
adherence and relapse.
Methods
Participants
Adult patients aged 18–60 years old with a Structured Clinical Interview for DSM-IV
(SCID-IV) diagnosis of schizophrenia or related psychoses were recruited from March 2007
to March 2010. All patients were found capable to participate in the study using the
McArthur Competence Assessment Tool for Clinical Research (Appelbaum and Grisso,
2001). Exclusion criteria were: a history of intolerance or contraindication to ziprasidone,
treatment with long-acting antipsychotics (within the past 6 months before entry), substance
abuse or dependence (within the past 6 months), pregnancy, clinically significant
abnormality in electrocardiography including a QTc interval of 450 msec or greater at the
time of screening, co-treatment with medications known to affect QTc interval, annual
radiation dose that would exceed 20mSv, a history of significant head trauma, unstable or
uncontrolled medical conditions. The study was approved by the Research Ethics Board of
the Centre for Addiction and Mental Health, Toronto, Canada, and all participants provided
written informed consent. This trial has been registered in ClinicalTrials.gov (Identifier
NCT00818298).
Treatment with ziprasidone
PET scanning was completed in eligible patients who were maintained on oral ziprasidone
monotherapy at 120 mg/day in two equally divided doses for at least 1 week. Enrolled
patients previously maintained on antipsychotics other than ziprasidone were switched to
ziprasidone at a starting dosage of 20 mg twice a day, then titrated to 60mg twice a day.
Patients previously maintained on olanzapine >5mg per day completed a one-week cross-
titration to minimize the risk for withdrawal effects. Patients previously maintained on
ziprasidone were kept on a dosage of 60 mg twice a day for at least 1 week prior to
scanning. Study medication was dispensed in blister packs and adherence was monitored
through pill count at each visit. All psychotropic agents other than ziprasidone were kept
constant throughout the study and patients taking any psychotropics known to affect
dopamine blockade other than ziprasidone were excluded from the study.
Assessments
The following scales were used to assess participants at baseline and at the time of each PET
scan - Clinical Global Impression (CGI) (Guy W (1976). Clinical Global Impressions. In:
ECDEU Assessment Manual for Psychopharmacology) and the Positive and Negative
Syndrome Scale (PANSS).
PET image acquisition
[11C]-raclopride PET scans were completed at one of three time points following 60mg of
oral ziprasidone: (Mean+SD) 287±12 minutes, 768±81 minutes, and 1402±46 minutes.
Patients were taking ziprasidone twice daily, 60mg each in the morning and at night, and
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one night dose was skipped before the 23-h scan. Usually patients had 13-h scan in the
morning after taking ziprasidone the night before, then again took the medication
immediately after finishing the morning scan and scanned 5 hours late, although this
schedule was slightly modified according to the availability of the PET camera. We refer to
these as the 5-hour, 13-hour and 23-hour scans, respectively. We used a high-resolution
neuro-PET camera system CPS-HRRT (Siemens Medical Imaging, Knoxville, TN, USA),
which measures radioactivity in 207 brain sections with a thickness of 1.2mm each. The in-
plane resolution of the scanner was 2.8mm full-width at half-maximum. Transmission scans
were acquired for five minutes using a single photon point source, 137Cs (T=30.2yr,
Eγ=662keV) and used to correct the emission scans for the attenuation of 511keV photons
through tissue and head support. The emission data were acquired in list mode, thereby
affording the highest possible temporal resolution. A custom-fitted thermoplastic mask (Tru-
Scan Imaging, USA) was made for each subject and used with a head fixation system during
PET scans in order to reduce any movement during the acquisition. No statistical differences
were observed in injected dose, specific activity and mass of [11C]-raclopride among the
PET scan sessions. A mean radioactivity dose of 9.91±0.71mCi with a specific activity of
2000±621mCi/mmol and mass of 1.92±0.72μg was injected as a bolus, followed by a flush
with 2ml saline into an intravenous line placed in an antecubital vein. Scanning time was 60
minutes and 28 frames (5 one-minute, 20 two-minute, and 3 five-minute frames) were then
defined.
MRI image acquisition
Patients were scanned with a 1.5T Signa scanner (General Electric Medical Systems,
Milwaukee, WI) to acquire a proton density image (TE=17, TR=6000, FOV=22cm 2D,
256x256, slice thickness of 2mm, NEX=2). The MRI images were used for the analysis of
the PET scans.
Image Analysis
The analysis of the PET images was performed as previously described (Graff-Guerrero et
al. 2008). The quantitative estimate of binding was estimated using the Simplified Reference
Tissue Method (SRTM) (Lammertsma et al. 1996) with the cerebellar cortex as the
reference region and caudate, putamen and ventral striatum as regions of interest (ROIs).
This method has been validated to reliably estimate binding potential nondisplaceable
(BPND), which is the typical measurement from reference tissue methods, as it compares the
concentration of radioligand in receptor-rich to receptor-free regions (Innis et al. 2007).
BPND was estimated using the software PMOD v2.7 (PMOD Technologies Ltd., Zurich,
Switzerland).
Receptor occupancy was defined as the percentage of reduction in the BPND from a baseline
state to the treated state. In order to calculate receptor occupancy, a measure of baseline
BPND in the antipsychotic-free (untreated) state was necessary. Since we were unable to
obtain the baseline measures of receptor occupancy from the patients (when they were
antipsychotic free) within our current design, we extrapolated the baseline BPND for each
subject using our pooled data previously obtained from 44 age- and sex-matched healthy
controls.
The occupancies were estimated with the following formula:
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Nonlinear regression analysis was applied to correlate the plasma level of ziprasidone with
receptor occupancy. The data was fitted to a rectangular hyperbola (one-site binding model)
described by the equation: , where ED50
represents the serum level of ziprasidone resulting in 50% receptor occupancy and “X”
corresponds to the ceiling receptor occupancy. In the model, X was fixed to 100 and ED50
>0. The ED50 was estimated for the ROIs combined. The time-course of receptor occupancy
across the ROIs, indicating a central receptor occupancy half-life, was estimated by a 1-
phase exponential decay equation:, where half-life is 0.6932/K and “X” corresponds to the
ceiling receptor occupancy.
Serum ziprasidone and prolactin quantification
Serum ziprasidone levels were obtained immediately before tracer injection and before the
end of the PET scan, 60 minutes apart, and the average value whenever available was used
to estimate the ED50. They were determined using liquid chromatography with mass
spectroscopy detection. Deuterated ziprasidone was used as the internal standard.
Calibration curves were linear from 7.5 to 600 nmol/L, with 7.5 nmol/L being the limit of
quantification and 3.0 nmol/L the limit of detection. The intra-assay coefficient of variation
was less than 5%. Serum prolactin was measured immediately before tracer injection using
the Beckman Coulter Access 2 instrument (reference range: male 3–13 ug/L; female 3–27
ug/L). The methodology utilizes paramagnetic particles in a chemiluminescent
immunoassay. The reporting limit was 1 ug/L.
Statistical analysis
Wilcoxon signed rank test, Mann-Whitney’s U test, t-test and Spearman’s rank correlation
coefficient were utilized as applicable. Statistical analyses were performed with SPSS
(version 17.0, SPSS Inc, Chicago, Illinois) and a p-value of <0.05 was considered significant
(two-tailed).
Results
Sample characteristics
Fourteen ambulatory patients meeting eligibility criteria were enrolled in the study.
Antipsychotics prior to enrolling in the study were olanzapine (n=6), ziprasidone (n=4),
quetiapine (n=2), and risperidone (n=2). Two subjects (one on olanzapine and one on
risperidone) showed clinical deterioration during the switching/cross-titration and were
withdrawn from the study before completing the PET scans.
Twelve subjects (6 female) with a diagnosis of schizophrenia underwent the PET scanning
procedures. One subject did not complete the 13-hr scan due to clinical deterioration. In
another subject, the 5-hr scan data was not analyzable due to an interruption of the scan, and
the 23-hr scan data was not analyzable due to technical problems. Excluding these three
scans, there were 11 scans per time point. Participants were on average 37.4 (±12.8) years of
age and had a mean illness duration of 14.5 (±12.7) years. The study was not powered to
address the clinical efficacy of ziprasidone and the results are presented for descriptive
purposes only. The average total PANSS score for the 12 patients was 53.5 (±13.7) at
baseline while the CGI-severity was 2.9 (±1.2), reflecting an overall mild severity. From
baseline to the time of the respective PET scans, no significant differences were noted in any
of the PANSS sub-scales. Similarly, CGI-change scores did not reveal a pattern of clinical
deterioration during the scanning interval. At the time of the 5-/13-/and 23-hr scans, CGI-
change scores compared to baseline were 3 (minimally better) for 2/3/1 patients, 4 (no
change) for 7/6/8, and 5 (minimally worse) for 2/2/2, respectively.
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Serum ziprasidone and prolactin levels
Figure 1 shows ziprasidone levels both before and after each PET scan. For 1 patient, post-
scan level was not available and pre-scan level (at 23 hours post-dose) was utilized for
analysis. Pre-scan ziprasidone levels were higher both at 5 hours versus 13 hours (Z=−2.578,
p=0.010), and higher at 13 hours versus 23 hours (Z=−2.934, p=0.003). Pre-scan levels were
significantly higher than post-scans at 13 hours in all cases. At 5 hours, pre-scan levels were
higher than post-scan levels in 10 of 12 subjects but the difference did not reach statistical
significance. At 23 hours, pre- and post-scan levels did not differ significantly.
Prolactin levels were higher than the reference range in 7 patients at 5-hour (mean±SD:
23.5±13.6 ug/L, n=12), 2 at 13-hour (9.6 ±−9.4 ug/L, n=11) and 0 at 23-hour (5.1±3.7 ug/L,
n=12). Prolactin levels were higher at 5 hours than 13 hours (Z=−2.934, p=0.003), and
higher at 13 hours than 23 hours (Z=−1.994, p=0.046).
PET data
Radiochemical characteristics of raclopride at 5-, 13-, and 23-hour postziprasidone scans
were as follows: injected dose 10.1 ± 0.69, 9.75 ± 0.82, and 9.90 ± 0.65 mCi; specific
activity 2230 ± 573, 1792 ± 699, and 1979 ± 557 mCi/mmol; injected mass 1.68 ± 0.49,
2.18 ± 0.90, and 1.90 ± 0.69 μg, with no significant differences in the values across the
scans. As is shown in Table 1 and Figure 3, ziprasidone produced a clinically relevant D2/3
receptor occupancy 5 hours after administration in the ROIs, which decreased at 13 hours
and was equivalent to the baseline level of controls in 23 hours. There were no significant
differences between the left and the right ROIs.
Figure 2 shows serum ziprasidone levels versus D2/3 occupancy across the ROIs. There was
a significant positive correlation in the putamen (n=33, rho=0.802, p=0.000), caudate (n=33,
rho=0.846, p=0.000) and ventral striatum (n=33, rho=0.789, p=0.000). The ED50 across the
ROIs was estimated to be 204nmol/L (84ng/ml; 95% confidence interval: 177–231nmol/L;
R2=0.68). The corresponding value was 174 nmol/L for putamen, 205 nmol/L for caudate
and 190 nmol/L for ventral striatum. The time-course of receptor occupancy across ROIs
indicated an occupancy half-life of 8.3 hours (95% confidence interval: 4.6–39 hours;
R2=0.56).
Discussion
To our knowledge, there have been 5 published PET studies evaluating central dopamine
occupancy by ziprasidone (Bench et al. 1996; Bench et al. 1993; Lammertsma et al. 1996;
Mamo et al. 2004; Vernaleken et al. 2008). However, this is the first study to assess
ziprasidone’s central binding at 3 time points using a within-subject design. Our results
indicate that ziprasidone, as dosed in this study, has a mean occupancy of 66% in the
putamen 5 hours after administration, which then declines to 39% at 13 hours and 2% at 23
hours, corresponding to an estimated central half-life of ziprasidone of 8.3 hours. Thus, the
time-course of the drug’s central binding mirrors its known peripheral pharmacokinetics
(peripheral half-life of 6–7 hours).
The serum ziprasidone levels we observed 13 hours post-dose in this study (150±103 nmol/
L; median: 114 nmol/L) are consistent with data reported at trough in a larger therapeutic
drug monitoring sample (median: 125 nmol/L for 120 mg/day) (Cherma et al. 2008). In
contrast, the occupancy at 13 hours (39±26%) was slightly lower than that reported in
previous PET studies (Mamo et al. 2004; Vernaleken et al. 2008), as well as a single photon
emission tomography study that found D2/3 receptor occupancy of 60% at 12 hours post-
dose (Corripio et al. 2005). We observed no appreciable drug binding 23 hours after the last
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dose of 60 mg, consistent with an earlier report in healthy subjects using a single dose of 40
mg (Bench et al. 1996).
Our results contrast with those reported by Vernaleken et al. (Vernaleken et al. 2008),
possibly attributable to differences in study design and methodology. Specifically,
Vernaleken et al. (Vernaleken et al. 2008) did not employ a within subject design, but
instead compared occupancy in 7 subjects 7.4 hours after ziprasidone administration and in
8 other subjects 21.4 hours after ziprasidone administration. By employing a within-subject
design, our study presumably better controls for the large inter-individual variability in the
pharmacokinetics and dopamine D2/3 receptor occupancy of ziprasidone over time. Notably,
Vernaleken et al. also used higher doses in their study (range: 120–200 mg/day; mean±SD
153±34 mg/day), versus a fixed dose of 60mg BID in our study.
We found the serum level of ziprasidone resulting in 50% receptor occupancy was estimated
to be 84 ng/ml, which was higher than the previously reported values of 39–64 ng/ml
(depending on the brain region) by Vernaleken et al. (2008) and 33 ng/ml by Mamo et al.
(2004). It has been pointed out that a range of 50–200 ng/ml for ziprasidone may be
effective (Hiemke et al. 2011) but it has also been identified that heterogeneity in levels is
substantial with hits medication, both centrally (Gründer et al. 2011) and peripherally
(Cherma et al. 2008). While this point is highly relevant in trying to translate the results of
PET data to peripheral therapeutic drug monitoring (TDM) that is more easily applicable,
and efforts are ongoing to better model pharmacokinetics of the medication (Wessels et al.
2011) and to predict central occupancy levels using peripheral drug levels (Uchida et al.
2011), it has been reported that blood levels of ziprasidone failed to well filter out
responders, with no correlations observed between improvements or side effects and doses
or serum levels (Vogel et al. 2009). As such TDM of ziprasidone may currently be of
limited use in the real-world clinical practice although more studies are necessary.
Our results bear closer resemblance to those with quetiapine and clozapine for which no
occupancy has been shown one day after the last dose (Kapur et al. 2000b; Kapur et al.
1999; Mamo et al. 2008; Suhara et al. 2002); they also stand in a sharp contrast to the longer
central than peripheral pharmacokinetics reported with olanzapine and risperidone (Tauscher
et al. 2002) as well as aripiprazole (Grunder et al. 2008). However, ziprasidone, which has a
dissociation constant (K) between 2.7nM and to 6 nM, exhibits in vitro more than 20-fold
higher affinity for the dopamine D2 receptors in comparison to clozapine (K=76 to 180 nM)
and quetiapine (K=140 to 680 nM) (Seeman 2011). The rapid central decrease in D2/3
receptor occupancy we observed with ziprasidone may entirely be associated with a short
central half-life that mirrors the peripheral half-life. This is in contrast to the combination of
loose binding, fast dissociation and short central half-life described with quetiapine (Kapur
et al. 2000b) and clozapine (Suhara et al. 2002). In addition, the short central occupancy
half-life may contribute to its relatively low incidence of EPS at clinical doses (Citrome
2009). The time-course of striatal occupancy also was mirrored by a similar rate of decline
in plasma prolactin levels, lending further support to our main finding. Further a marked
discrepancy in occupancy values between single and multiple dose administration has been
observed with ziprasidone (Vernaleken et al. 2008). Potential upregulation in D2 receptors
upon chronic administration of ziprasidone (Heard et al. 2008) might account for somewhat
higher binding potentials after 23 hours in patients than controls and worsening that was
noted in some patients as well. Taken together, more work is necessary to better characterize
this unique antipsychotic medication that binds tightly to dopamine receptors.
A major strength of this study is its within-subject design using [11C]-raclopride, a
radiotracer with well-established test-retest stability (Uchida et al. 2009), and any residual
effects from the previous antipsychotis are unlikely to affect dopamine blockade with
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ziprasidone under a steady state in a significant manner. Limitations of this study include a
relatively small number of participants, precluding analysis of differences between
responders and non-responders. Similarly, observed gender differences warrant replication
in view of the small sample. The absence of baseline (untreated) PET data in subjects with
schizophrenia is another potential limitation shared with most PET studies examining
antipsychotic medications in patients with schizophrenia. However, having a “baseline” scan
in the absence of any antipsychotics would be difficult and can be ethically problematic.
Further, exposing subjects to many PET scans is not without risks and our facility regulates
that a volunteer can have only up to 4 PET scans per year to protect safety. In addition, the
magnitude of the error due to using a baseline obtained from healthy controls is estimated to
be low: 0–4% for patients with an 80% occupancy and 0–9% for those with a 50%
occupancy (Farde et al. 1992; Kapur et al. 1996), although a small elevation in receptor
availability is still possible (Howes et al. 2012) and caution is warranted in extrapolating
data from healthy controls. Our interest was confined to striatal dopamine D2/3 receptors
using [11C]-raclopride. While ziprasidone may show some preferential extrastriatal binding
(Vernaleken et al. 2008), the affinity of [11C]-raclopride for dopamine D2/3 receptors
precludes accurate measurements of binding in extrastriatal regions. Furthermore,
ziprasidone acts on multiple receptors and transporters (Stahl and Shayegan 2003) including
serotonergic 5-HT2A receptors for which central kinetics is reported to be longer (Fischman
et al. 1996), as well as 5-HT1A receptors (Frankle et al. 2011). Finally, our study adopted a
fixed-dose design that might not reflect its dosing in clinical situations (Citrome et al. 2009).
We found that 13 hours after the last dose of ziprasidone, the dopamine D2/3 occupancy was
well below the suggested 60% therapeutic threshold for PET studies with [11C]-raclopride.
This time is expected to reflect the trough occupancy when ziprasidone is taken twice a day.
Some antipsychotics such as clozapine and quetiapine have been shown to be clinically
effective notwithstanding the fact that they are associated with transient and/or loose binding
at D2/3 receptors (Kapur et al. 2000b; Mamo et al. 2008; Nordstrom et al. 1995; Pickar et al.
1996). This raises the possibility that ensuring 24-hour continuous D2/3 blockade above
60%, as predicted by the drugs’ pharmacokinetics, may not be a prerequisite to maintain
wellness in schizophrenia. Nevertheless, our results suggest that in order to maintain
continuous dopamine D2/3 receptor blockade, ziprasidone should be administered in its
currently recommended divided dosage. In published studies, and in this study, some
patients remain stable when they receive ziprasidone twice a day. However, more work is
necessary to understand how the central occupancy of antipsychotics like ziprasidone relates
to their clinical efficacy and tolerability. Well-designed clinical studies are necessary to
quantify the risks and benefits of once daily versus twice-daily dosing of ziprasidone.
This study was the first to examine within-subject changes in ziprasidone’s occupancy at the
dopamine D2/3 receptors over 24-hours using [11C]-raclopride. Our findings lead us to
support that there is not discrepancy between the time course of ziprasidone’s plasma
concentration and dopamine D2/3 receptor occupancy in the brain.
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Figure 1.
Serum ziprasidone level before and after each PET scan. Each symbol represents the same
individual.
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Figure 2.
Relationship between ziprasidone serum levels and D2 receptor occupancy in regions of
interest. The line corresponds to the fitting to one-site binding model across the regions of
interest (ED50 = 204 nmol/L, R2 = 0.68). The occupancies in negative values were excluded
from the graph and no considered to estimate the ED50.
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Figure 3.
[11C]-raclopride binding potential non-displaceable maps. Images correspond to averaged
[11C]-raclopride binding potential maps of healthy controls (n=44) and patients with
schizophrenia after 5-hour (n=11), 13-hour (n=11) and 23-hour (n=11) of the last dose of
ziprasidone (60 mg). The binding potential maps are presented with an absolute threshold
between 0 and 7 and in axial projection illustrating the dorsal striatum regions.
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